Vaccines made from peptides that are found on the surface of leukemia cells may make the body generate an immune response and kill cancer cells. Recently, studies have shown promise for the PR1 peptide vaccine, a nine amino acid HLA-A2 restricted peptide derived from proteinase 3. An immune response to this particular peptide has been seen in leukemia patients who were in remission. Now, in a study of myeloid leukemia, a team of researchers from the University of Texas M.D. Anderson Cancer Center have shown complete molecular remissions in some patients with significantly improved event-free survival among those who have an immune response.
Go to Previous Page
Go to Next Page